Home » Stocks » KRYS

Krystal Biotech, Inc. (KRYS)

Stock Price: $65.89 USD -4.89 (-6.91%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 1.51B
Revenue (ttm) n/a
Net Income (ttm) -32.17M
Shares Out 18.79M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $65.89
Previous Close $70.78
Change ($) -4.89
Change (%) -6.91%
Day's Open 69.85
Day's Range 63.69 - 71.79
Day's Volume 108,142
52-Week Range 37.68 - 87.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinica...

1 week ago - GlobeNewsWire

PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistica...

2 weeks ago - GlobeNewsWire

PITTSBURGH, April 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced positive results of its IND-ena...

3 weeks ago - GlobeNewsWire

PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete in ...

1 month ago - GlobeNewsWire

PITTSBURGH, March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming v...

1 month ago - GlobeNewsWire

-  Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections

1 month ago - GlobeNewsWire

- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21.

2 months ago - GlobeNewsWire

PITTSBURGH, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan, Chairman...

2 months ago - GlobeNewsWire

PITTSBURGH, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previou...

3 months ago - GlobeNewsWire

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwrit...

3 months ago - Business Wire

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD, FRCS, FMe...

4 months ago - Business Wire

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief executive ...

5 months ago - Business Wire

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today...

6 months ago - Business Wire

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Seni...

6 months ago - Business Wire

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS) today announced the presentation of positive preclinical data supporting the ongoing development of KB301, an innovative, investigational...

7 months ago - Business Wire

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) pl...

7 months ago - Business Wire

PITTSBURGH, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus ty...

8 months ago - GlobeNewsWire

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection 

8 months ago - GlobeNewsWire

The company is on track to file an IND for KB407 in 2021 The company is on track to file an IND for KB407 in 2021

8 months ago - GlobeNewsWire

Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients

9 months ago - GlobeNewsWire

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus typ...

9 months ago - GlobeNewsWire

PITTSBURGH, July 28, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (H...

9 months ago - GlobeNewsWire

PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (H...

9 months ago - GlobeNewsWire

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by...

11 months ago - GlobeNewsWire

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by...

11 months ago - GlobeNewsWire

KB105 was well tolerated with no adverse events or immune response following redosing

11 months ago - GlobeNewsWire

KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative Dermatology (SID) Annual Meeting in May 2020

1 year ago - GlobeNewsWire

Krystal Biotech: Revisiting This Gene Therapy Pioneer Ahead Of Q2 Data

1 year ago - Seeking Alpha

PITTSBURGH, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, announced today the ground breaking of the seco...

1 year ago - GlobeNewsWire

PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chi...

1 year ago - GlobeNewsWire

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).

1 year ago - Zacks Investment Research

Despite soaring already, these biotech stocks aren't finished climbing.

Other stocks mentioned: AXSM, KOD
1 year ago - The Motley Fool

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors?

1 year ago - Zacks Investment Research

PITTSBURGH, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suff...

1 year ago - GlobeNewsWire

Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be market disruptive.

1 year ago - Seeking Alpha

Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be market disruptive.

1 year ago - Seeking Alpha

PITTSBURGH, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation...

1 year ago - GlobeNewsWire

PITTSBURGH, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffe...

1 year ago - GlobeNewsWire

It was a great week for these three stocks, but can they continue climbing?

Other stocks mentioned: DOVA, MGTX
1 year ago - The Motley Fool

Krystal Biotech Inc (NASDAQ: KRYS) announced positive Phase 2 data for KB103 Monday and said the gene therapy received the Regenerative Medicine Advanced Therapy designation from the FDA.

1 year ago - Benzinga

In recent Krystal Biotech news, KRYS stock is soaring as the company's drug designed to treat a skin condition received expedited FDA review. The post Krystal Biotech News: Why Is KRYS Stock Soaring Today?

1 year ago - InvestorPlace

Krystal Biotech Inc (NASDAQ: KRYS) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday.

1 year ago - Benzinga

Shares of Krystal Biotech Inc. were up 27% in Monday intraday trade after the gene therapy company said it had received an expedited review designation from the FDA for its lead drug candidate to treat ...

1 year ago - Market Watch

We are now approaching the second half of 2019. And it may be time for a little portfolio rebalancing.

Other stocks mentioned: BMRN, DRNA, GBT, IOVA
1 year ago - InvestorPlace

Krystal Biotech Inc. is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017.

2 years ago - Seeking Alpha

About KRYS

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scar... [Read more...]

Industry
Biotechnology
IPO Date
Sep 20, 2017
Stock Exchange
NASDAQ
Ticker Symbol
KRYS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price forecast is 98.80, which is an increase of 49.95% from the latest price.

Price Target
$98.80
(49.95% upside)
Analyst Consensus: Strong Buy